Epidemiology of Antimicrobial-use and Antimicrobial-resistant Infections in Four Hospitals in Thailand

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorUniversity of Oxford

About this trial

The main goal of this retrospective observational study is to understand how stepping down antibiotic treatment (called antibiotic de-escalation) affects patients who receive it compared to those who don't after received a short-course (≤7 days) of parenteral antibiotics. The investigators will use past medical records from four public referral hospitals in Thailand from the year 2019 to 2024. The investigators will firstly evaluate which types of patients are more likely to receive antibiotic de-escalation. Then, the investigators will estimate the impact of antibiotic de-escalation, while taking those differences into account. This way, it will help us understand the impact of antibiotic de-escalation in real-world clinical practice. The investigators also aim to assess how accurate automated outbreak detection systems are at detecting outbreaks, evaluate patterns of antimicrobial use and antimicrobial-resistant infections, and develop new indicators for antimicrobial stewardship that are applicable for local and national actions in low and middle-income countries.

Eligibility criteria

Qualifiers

Admitted to four collaborating hospitals from 1 Jan 2019 to 31 Dec 2024

Received a parenteral antibiotic for at least four consecutive days

Were still hospitalized on day 8 after starting a parenteral antibiotic

Disqualifiers

Admitted as day admissions to four collaborating hospitals from 1 Jan 2019 to 31 Dec 2024

Had a clinical specimen collected within 2 calendar days of starting a parenteral antibiotic culture positive for an antimicrobial-resistant organism or Staphylococcus aureus

All age and gender

Admitted to four collaborating hospitals from 1 Jan 2019 to 31 Dec 2024

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

108,000 Participants
are grouped into 3 trial groups

Sponsors and collaborators

University of Oxford

Lead sponsor

Wellcome Trust

Collaborator